

Felix Chua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1362695/publications.pdf>

Version: 2024-02-01

26
papers

1,196
citations

516710

16
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

1882
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 9-13.	2.9	268
2	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine, 2018, 6, 759-770.	10.7	145
3	Mice Lacking Neutrophil Elastase Are Resistant to Bleomycin-Induced Pulmonary Fibrosis. American Journal of Pathology, 2007, 170, 65-74.	3.8	130
4	Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics. Annals of the American Thoracic Society, 2019, 16, 1351-1359.	3.2	110
5	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine, 2020, 8, 438-440.	10.7	74
6	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	3.7	57
7	Clinical utility of existing and second-generation interferon- γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infectious Diseases, 2019, 19, 193-202.	9.1	47
8	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	5.6	45
9	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	6.7	42
10	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	6.7	34
11	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	6.7	32
12	Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	2.3	30
13	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.8	28
14	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
15	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	2.6	24
16	Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax, 2021, 76, 696-703.	5.6	24
17	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	5.6	15
18	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	5.6	14

#	ARTICLE	IF	CITATIONS
19	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1901681.	6.7	11
20	Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. <i>Respirology</i> , 2022, 27, 202-208.	2.3	11
21	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. <i>Respiratory Medicine</i> , 2016, 120, 131-133.	2.9	8
22	Retrospective case-control study to evaluate hypocalcaemia as a distinguishing feature of COVID-19 compared with other infective pneumonias and its association with disease severity. <i>BMJ Open</i> , 2021, 11, e053810.	1.9	7
23	An emerging interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2016, 4, 762.	10.7	2
24	Transbronchial cryobiopsy for diagnosis of pleuroparenchymal fibroelastosis. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101164.	0.4	2
25	Images of the month 1: Cough before the storm: A case of pulmonary alveolar microlithiasis. <i>Clinical Medicine</i> , 2020, 20, 110-111.	1.9	2
26	Delays in idiopathic pulmonary fibrosis diagnosis and treatment: Time for change. <i>Respirology</i> , 2022, 27, 10-11.	2.3	1